Kaitlyn D’Onofrio

DocwireNews

Patients with postmenopausal estrogen receptor-positive breast cancer commonly receive five-year adjuvant treatment with aromatase inhibitors, although these are sometimes associated with adverse events (AEs) that affect a patient&rsquo;s quality of life and can lead to treatment discontinuation. Some AEs associated with aromatase inhibitors include joint and vasomotor symptoms. A prospective cohort study explored how AEs affect prognosis in Japanese patients with postmenopausal breast cancer receiving adjuvant anastrozole, based on patient-reported outcomes (PROs). The findings of the study were presented at the San Antonio Breast Cancer Symposium.The study included 391 patients from 28 centers. PRO assessments were conducted at baseline and three, six nine, and 12 months. Symptoms were classified as none (G0), mild (G1), moderate (G2), and severe (G3). Topics covered in the assessments included joint symptoms (arthralgia, decrease in range of joint motion, and joint stiffness), vasomotor symptoms (hot flashes, night sweats, and cold sweats), and adherence to anastrozole. Patients were followed for a median of 82 months.Just more than half of patients (n=204; 52.2%) complete five-year treatment: 75 patients (19.2%) discontinued due to AEs (n=35), recurrence (n=19), secondary malignancies (n=4), non-breast cancer death (n=4), and other reasons (n=13). Forty-eight patients (12.3%) are currently receiving treatment, and 64 (16.4%) were unknown. Disease-free survival (DFS) was significantly better in patients with G2 and G3 joint symptoms than patients with G0 and G1 joint symptoms (five-year DFS, 96.1% vs. 83.3%; P=0.002). The same pattern was observed with vasomotor symptoms (five-year DFS, 93.5% vs. 86.3%, respectively; P=0.049). A slight association was observed between joint symptoms and overall survival (OS; P=0.062), but no correlation presented between vasomotor symptoms and OS.&ldquo;The DFS was superior in patients with G2 and G3 joint and vasomotor symptoms (five-year DFS, 100%), inferior in those with G0 and G1 joint and vasomotor symptoms (five-year DFS, 82.6%), and intermediate in others (five-year DFS, 93.3%; P=0.0024),&rdquo; according to the researchers.Multivariable analyses considering tumor size and grade found that G2 and G3 joint symptoms significantly and independently predicted DFS (hazard ratio, 0.298; 95% confidence interval, 0.122-0.621; P=0.0007).

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Do Aromatase Inhibitor-Related AEs Affect Disease Prognosis?

San Antonio Breast Cancer Symposium 2019

Patients with postmenopausal estrogen receptor-positive breast cancer commonly receive five-year adjuvant treatment with aromatase inhibitors, although these are sometimes ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe